One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration
Sign Up to like & getrecommendations! Published in 2021 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-07087-6
Abstract: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze the performance of the COMBO stent… read more here.
Keywords: stemi; combo stent; acs; year ... See more keywords
Obtaining turbulence statistics of thermally driven anabatic flow by sonic-hot-film combo anemometer
Sign Up to like & getrecommendations! Published in 2018 at "Environmental Fluid Mechanics"
DOI: 10.1007/s10652-018-9649-x
Abstract: Achieving a better understanding of atmospheric boundary layer flows, and of slope flows in particular, is of paramount importance for the research of climate processes and production of accurate weather forecasts. We addressed the need… read more here.
Keywords: thermally driven; driven anabatic; turbulence; turbulence statistics ... See more keywords
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what’s the current standard of care?
Sign Up to like & getrecommendations! Published in 2024 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2024.2409438
Abstract: ABSTRACT Introduction JAK inhibitors (JAKi) have changed the treatment paradigm of myelofibrosis (MF). Currently, 4 JAKis are approved in the US as monotherapy (mono) to treat patients with MF. JAKis are also being studied in… read more here.
Keywords: novel agents; kinase inhibitor; combination; combo ... See more keywords
MO624COMBINATION TREATMENT WITH LISINOPRIL AND EMPAGLIFLOZIN IMPROVES BIOCHEMICAL AND HISTOLOGICAL MARKERS OF DIABETIC NEPHROPATHY IN HYPERTENSIVE UNINEPHRECTOMIZED DB/DB MICE
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab093.005
Abstract: Emerging treatments of diabetic kidney disease (DKD) include SGLT2 inhibitors and GLP-1 receptor agonists that are nephroprotective beyond their blood glucose lowering effects. Despite this progress, patients with diabetes are still at risk of developing… read more here.
Keywords: vehicle; combo; mice; treatment ... See more keywords
Delivering guideline-directed medical therapy for heart failure with reduced ejection fraction as an over-encapsulated polypill: rationale and protocol for the COMBO-HF-X pilot crossover randomised clinical trial
Sign Up to like & getrecommendations! Published in 2025 at "BMJ Open"
DOI: 10.1136/bmjopen-2024-093663
Abstract: Introduction A four-drug regimen of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) is underused, in part due to prescriber inertia and low patient adherence. Although fixed-dose combination pills (‘polypills’) have… read more here.
Keywords: combo; hfref; trial; medical therapy ... See more keywords
Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194610
Abstract: Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare, acquired, life-threatening disorder, characterized by hemolysis and an increased risk of thrombosis often co-existing with bone marrow insufficiency. Standard of care includes C5 inhibitors, given as chronic… read more here.
Keywords: treatment; combo; pozelimab; ravu ... See more keywords
Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-199281
Abstract: Introduction: Cyclin-dependent kinase 9 (CDK9), a key regulator of transcription elongation, is a potential target in transcriptionally addicted cancers dependent on oncogenic drivers with short half-lives such as MYC, MYB, and MCL1. PRT2527, an investigational,… read more here.
Keywords: cdk9; monotherapy combo; combo; prt2527 monotherapy ... See more keywords
Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4519
Abstract: 4519 Background: INDUCE-1 is a first-in-human trial evaluating fela, an IgG4 ICOS agonist non-T-cell depleting mAb, as monotherapy (mono) and in combo with P. ECs include tumor types, such as UC, with high ICOS expression… read more here.
Keywords: combo; fela; activity; disease ... See more keywords
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.2533
Abstract: 2533 Background: Most pts with mNSCLC without actionable gene alterations have limited options after progression on first-line checkpoint inhibitor (CPI)–containing treatment (tx). Given failures of recent trials in this setting, single-agent chemotherapy remains the main… read more here.
Keywords: combo; trial; pts mnsclc; pembro ... See more keywords